On June 20th, ASBM Chairman Harry L. Gewanter, MD presented a poster based on ASBM’s survey of Australian biologic prescribers, at the DIA 2017 Annual Meeting in Chicago, IL. ASBM exhibited at DIA from June 19th-21st.
The survey included 76% of prescribers believed the Therapeutic Goods Administration (TGA) should assign distinct names to all biologics, including biosimilars.
Also, 90% considered it “very important” or “critical” that the prescribing physician, with their patient, have the authority to choose the most suitable biologic for treatment. Eighty-nine percent considered it “very important” or “critical” to be notified in the event a biosimilar is substituted at the pharmacy.
View the full poster here.